Oxaflozane
 | |
| Clinical data | |
|---|---|
| Trade names | Conflictan |
| Other names | CERM-1766 |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
Oxaflozane (
overdose.[6]
See also
References
- ISBN 978-1-4757-2085-3.
- ISBN 3-88763-075-0.
- ISBN 0-8155-1144-2.
- ^ ISBN 978-0-470-28187-1.
- PMID 16160946.
- PMID 1542141.
Further reading
- Rascol A, Maurel H, David J, Layani M (1974). "[Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane]". Thérapie (in French). 29 (1): 95–9. PMID 4603757.
- Hache J, Duchene-Marullaz P, Streichenberger G (1974). "[Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)]". Thérapie (in French). 29 (1): 81–93. PMID 4849381.
- Constantin M, Pognat JF (1979). "Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites". Arzneimittel-Forschung. 29 (1): 109–14. PMID 582104.
- Bertolino A, palermo M, Porro V (1985). "Un nouvel antidépresseur non tricyclique, l'oxaflozane, dans le traitement des syndromes anxio-dépressifs" [Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes]. Acta Therapeutica. 11 (2): 209–218.
- Aguglia E (1986). "On the therapetic value of oxaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations". Acta Therapeutica. 12 (3): 259–268.